VRX - Valeant Pharmaceuticals Intern
This page shows which of the focused investors we track hold VRX and how their positions changed, so you can see how much conviction the group has in the stock.
In Q4 2015 it was held by 11 managers with an aggregate reported value of $9.39B, which is 1.25% of the combined portfolio.
As of Q4 2015, 11 tracked institutional managers held VRX (Valeant Pharmaceuticals Intern) with an aggregate reported value of $9.39B — 1.25% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades VRX — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q4 2015
- Ticker
- VRX
13F data is delayed and excludes shorts/non-13F assets.
Long holders
| 1 | Ruane Cunniff LP - Ruane Cunniff LP | 20.49% | Add +4.3% | 35,375,610 | $3.6B |
| 2 | Bill Ackman - Pershing Square Capital Management | 13.54% | Reduce -14.8% | 16,591,122 | $1.69B |
| 3 | ValueAct Capital - ValueAct Capital | 10.55% | - | 14,994,261 | $1.52B |
| 4 | Viking Global Investors - Viking Global Investors | 2.99% | Add +56.1% | 7,793,397 | $792.2M |
| 5 | Glenn Greenberg - Brave Warrior Advisors | 25.22% | Add +12.1% | 6,252,331 | $635.55M |
| 6 | Stephen Mandel - Lone Pine Capital | 2.64% | Reduce -21.9% | 5,829,079 | $592.53M |
| 7 | Christopher Davis - Davis Advisors | 1.60% | Add +150.7% | 3,784,012 | $384.65M |
| 8 | First Eagle - First Eagle Investment Management | 0.42% | Add +55.4% | 1,640,132 | $166.72M |
| 9 | Francois Rochon - Giverny Capital | 2.58% | Add +1.9% | 127,735 | $12.98M |
Put holders — short bets
1 manager has put options on VRX — a right to sell at strike. The reported value is the underlying market value (notional), not the option premium paid.
| 1 | First Eagle - First Eagle Investment Management | Add +137.0% | 2,500 | $25K |
Call holders — bullish via leverage
1 manager holds call options on VRX — a right to buy at strike. Notional value, not premium.
| 1 | First Eagle - First Eagle Investment Management | New | 2,000 | $220K |